Target Name: OR13C2
NCBI ID: G392376
Review Report on OR13C2 Target / Biomarker Content of Review Report on OR13C2 Target / Biomarker
OR13C2
Other Name(s): OR37K | olfactory receptor OR9-12 | Olfactory receptor 13C2 | Olfactory receptor family 13 subfamily C member 2 | O13C2_HUMAN | olfactory receptor family 13 subfamily C member 2 | Olfactory receptor OR9-12

OR13C2: A Potential Drug Target and Biomarker

OR13C2 (OR37K), a protein that is expressed in the human placenta, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression pattern make it an attractive target for researchers to investigate, and its potential utility as a drug may have significant implications for the treatment of these diseases.

OR13C2 is a member of the OR family of transmembrane proteins, which are involved in various physiological processes in the body, including cell signaling, migration, and invasion. OR13C2 is expressed in the human placenta, which is a vital organ that plays a critical role in the development and maintenance of fetal tissues. The placenta is also a site of disease where many organisms, including viruses and bacteria, can replicate and cause infection. Therefore, OR13C2 has the potential to be a useful biomarker for tracking disease progression and evaluating the effectiveness of potential treatments.

OR13C2 has been shown to be involved in several important biological processes in the placenta, including the regulation of cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). It has been shown to play a role in the development and maintenance of the placenta, as well as the fetal microenvironment. OR13C2 has also been implicated in the regulation of pregnancy outcomes, including pregnancy loss and preterm delivery.

In addition to its role in the placenta, OR13C2 has also been shown to be involved in various diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, OR13C2 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and prostate cancer. This suggests that it may be a useful target for cancer therapies. OR13C2 has also been implicated in neurodegenerative diseases, including Alzheimer's and Parkinson's diseases, as well as autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

OR13C2 has also been shown to be involved in several cellular processes that are important for human health, including cell signaling, migration, and invasion. Its expression has been shown to be regulated by various factors, including Wnt signaling, TGF-β signaling, and NF-kappa-B signaling. These signaling pathways are involved in the regulation of cellular processes that are important for tissue growth, development, and function, including placenta development and fetal growth.

In conclusion, OR13C2 is a protein that has been shown to be involved in various biological processes that are important for human health. Its unique structure and expression pattern make it an attractive target for research into potential drugs and biomarkers. Further studies are needed to fully understand its role in the placenta and its potential utility as a drug target and biomarker.

Protein Name: Olfactory Receptor Family 13 Subfamily C Member 2

Functions: Odorant receptor

The "OR13C2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR13C2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR13C3 | OR13C4 | OR13C5 | OR13C8 | OR13C9 | OR13D1 | OR13F1 | OR13G1 | OR13H1 | OR13J1 | OR13Z2P | OR14A16 | OR14A2 | OR14C36 | OR14I1 | OR14J1 | OR14L1P | OR1A1 | OR1A2 | OR1B1 | OR1C1 | OR1D2 | OR1D4 | OR1D5 | OR1E1 | OR1E2 | OR1E3 | OR1F1 | OR1F2P | OR1G1 | OR1I1 | OR1J1 | OR1J2 | OR1J4 | OR1K1 | OR1L1 | OR1L3 | OR1L4 | OR1L6 | OR1L8 | OR1M1 | OR1N1 | OR1N2 | OR1P1 | OR1Q1 | OR1S1 | OR1S2 | OR2A1 | OR2A1-AS1 | OR2A12 | OR2A14 | OR2A2 | OR2A20P | OR2A25 | OR2A4 | OR2A42 | OR2A7 | OR2A9P | OR2AE1 | OR2AG1 | OR2AG2 | OR2AJ1 | OR2AK2 | OR2AL1P | OR2AM1P | OR2AP1 | OR2AT4 | OR2B11 | OR2B2 | OR2B3 | OR2B6 | OR2C1 | OR2C3 | OR2D2 | OR2D3 | OR2F1 | OR2F2 | OR2G2 | OR2G3 | OR2G6 | OR2H1 | OR2H2 | OR2I1P | OR2J1 | OR2J2 | OR2J3 | OR2J4P | OR2K2 | OR2L13 | OR2L1P | OR2L2 | OR2L3 | OR2L5 | OR2L8 | OR2L9P | OR2M1P | OR2M2 | OR2M3 | OR2M4 | OR2M5